A Phase I Study of Intravenous Irinotecan and Bortezomib in Children With Recurrent/Refractory High-Risk Neuroblastoma.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2019
At a glance
- Drugs Bortezomib (Primary) ; Irinotecan (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 03 Jul 2017 Status changed from active, no longer recruiting to completed.
- 15 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2016 as reported by ClinicalTrials.gov.